Physician profile
Aaron A Adaoag
NPI 1609834852
$7,095.72
in general payments reported to CMS, 2019-2025
22 companies · $703 in 2025
The $703 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,180 · 2020: $676 · 2021: $2,186 · 2022: $353 · 2023: $318 · 2024: $679 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,651.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,387.07 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $1,011.29 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $648.32 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $406.61 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $356.22 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $328.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.34 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $249.74 | 2019 | |
| Amarin Pharma, INC. | $124.63 | 2019-2021 | |
| Daiichi Sankyo INC. | $100.54 | 2019-2025 | Injectafer |
| Horizon Therapeutics Plc | $79.78 | 2019-2021 | |
| Pfizer INC. | $79.67 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $74.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.17 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $53.96 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $46.19 | 2022 | |
| Azurity Pharmaceuticals, INC. | $35.94 | 2023-2025 | Edarbi, Edarbi |
| Abbvie INC. | $33.68 | 2020-2021 | |
| Lucid Diagnostics INC. | $24.91 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $11.87 | 2019 | |
| Dexcom, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Adaoag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.